252 related articles for article (PubMed ID: 33596035)
1. Designing Mesoporous Silica Nanoparticles to Overcome Biological Barriers by Incorporating Targeting and Endosomal Escape.
Gisbert-Garzarán M; Lozano D; Matsumoto K; Komatsu A; Manzano M; Tamanoi F; Vallet-Regí M
ACS Appl Mater Interfaces; 2021 Mar; 13(8):9656-9666. PubMed ID: 33596035
[TBL] [Abstract][Full Text] [Related]
2. Protease-mediated release of chemotherapeutics from mesoporous silica nanoparticles to ex vivo human and mouse lung tumors.
van Rijt SH; Bölükbas DA; Argyo C; Datz S; Lindner M; Eickelberg O; Königshoff M; Bein T; Meiners S
ACS Nano; 2015 Mar; 9(3):2377-89. PubMed ID: 25703655
[TBL] [Abstract][Full Text] [Related]
3. A Sequentially Responsive Nanosystem Breaches Cascaded Bio-barriers and Suppresses P-Glycoprotein Function for Reversing Cancer Drug Resistance.
Liu J; Zhao L; Shi L; Yuan Y; Fu D; Ye Z; Li Q; Deng Y; Liu X; Lv Q; Cheng Y; Xu Y; Jiang X; Wang G; Wang L; Wang Z
ACS Appl Mater Interfaces; 2020 Dec; 12(49):54343-54355. PubMed ID: 32959645
[TBL] [Abstract][Full Text] [Related]
4. Mesoporous Silica Nanoparticles for Targeting Subcellular Organelles.
Gisbert-Garzarán M; Lozano D; Vallet-Regí M
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33353212
[TBL] [Abstract][Full Text] [Related]
5. TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance.
Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Cao X; Zhang H
Mater Sci Eng C Mater Biol Appl; 2018 Mar; 84():108-117. PubMed ID: 29519418
[TBL] [Abstract][Full Text] [Related]
6. Gated magnetic mesoporous silica nanoparticles for intracellular enzyme-triggered drug delivery.
An N; Lin H; Yang C; Zhang T; Tong R; Chen Y; Qu F
Mater Sci Eng C Mater Biol Appl; 2016 Dec; 69():292-300. PubMed ID: 27612716
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in mesoporous silica nanoparticles for antitumor therapy: our contribution.
Baeza A; Manzano M; Colilla M; Vallet-Regí M
Biomater Sci; 2016 May; 4(5):803-13. PubMed ID: 26902682
[TBL] [Abstract][Full Text] [Related]
8. A self-targeting and controllable drug delivery system constituting mesoporous silica nanoparticles fabricated with a multi-stimuli responsive chitosan-based thin film layer.
Chen C; Yao W; Sun W; Guo T; Lv H; Wang X; Ying H; Wang Y; Wang P
Int J Biol Macromol; 2019 Feb; 122():1090-1099. PubMed ID: 30219514
[TBL] [Abstract][Full Text] [Related]
9. Ultrasmall mesoporous organosilica nanoparticles: Morphology modulations and redox-responsive biodegradability for tumor-specific drug delivery.
Yu L; Chen Y; Lin H; Du W; Chen H; Shi J
Biomaterials; 2018 Apr; 161():292-305. PubMed ID: 29427925
[TBL] [Abstract][Full Text] [Related]
10. Intracellular pH-Triggered, Targeted Drug Delivery to Cancer Cells by Multifunctional Envelope-Type Mesoporous Silica Nanocontainers.
Yang K; Luo H; Zeng M; Jiang Y; Li J; Fu X
ACS Appl Mater Interfaces; 2015 Aug; 7(31):17399-407. PubMed ID: 26196506
[TBL] [Abstract][Full Text] [Related]
11. Facile synthesis of organosilica-capped mesoporous silica nanocarriers with selective redox-triggered drug release properties for safe tumor chemotherapy.
Shen L; Pan S; Niu D; He J; Jia X; Hao J; Gu J; Zhao W; Li P; Li Y
Biomater Sci; 2019 Apr; 7(5):1825-1832. PubMed ID: 30892297
[TBL] [Abstract][Full Text] [Related]
12. Anticancer Drug Delivery Capability of Biodegradable PMO in the Chicken Egg Tumor Model.
Matsumoto K; Le Hoang Doan T; Mai NXD; Nakai K; Komatsu A; Tamanoi F
Enzymes; 2018; 44():103-116. PubMed ID: 30360810
[TBL] [Abstract][Full Text] [Related]
13. Advances in Functionalized Mesoporous Silica Nanoparticles for Tumor Targeted Drug Delivery and Theranostics.
Zhang W; Liu M; Liu A; Zhai G
Curr Pharm Des; 2017; 23(23):3367-3382. PubMed ID: 27784244
[TBL] [Abstract][Full Text] [Related]
14. A comparison of mesoporous silica nanoparticles and mesoporous organosilica nanoparticles as drug vehicles for cancer therapy.
Yue J; Luo SZ; Lu MM; Shao D; Wang Z; Dong WF
Chem Biol Drug Des; 2018 Aug; 92(2):1435-1444. PubMed ID: 29671941
[TBL] [Abstract][Full Text] [Related]
15. Targeted intracellular delivery of hydrophobic agents using mesoporous hybrid silica nanoparticles as carrier systems.
Rosenholm JM; Peuhu E; Eriksson JE; Sahlgren C; Lindén M
Nano Lett; 2009 Sep; 9(9):3308-11. PubMed ID: 19736973
[TBL] [Abstract][Full Text] [Related]
16. Co-Delivery of Doxorubicin and Survivin shRNA-Expressing Plasmid Via Microenvironment-Responsive Dendritic Mesoporous Silica Nanoparticles for Synergistic Cancer Therapy.
Li Z; Zhang L; Tang C; Yin C
Pharm Res; 2017 Dec; 34(12):2829-2841. PubMed ID: 28948461
[TBL] [Abstract][Full Text] [Related]
17. Polymeric Engineering of Nanoparticles for Highly Efficient Multifunctional Drug Delivery Systems.
Fortuni B; Inose T; Ricci M; Fujita Y; Van Zundert I; Masuhara A; Fron E; Mizuno H; Latterini L; Rocha S; Uji-I H
Sci Rep; 2019 Feb; 9(1):2666. PubMed ID: 30804375
[TBL] [Abstract][Full Text] [Related]
18. Redox-responsive mesoporous silica nanoparticles: a physiologically sensitive codelivery vehicle for siRNA and doxorubicin.
Ma X; Teh C; Zhang Q; Borah P; Choong C; Korzh V; Zhao Y
Antioxid Redox Signal; 2014 Aug; 21(5):707-22. PubMed ID: 23931896
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of "on-demand" drug release using dual tumor marker mediated DNA-capped versatile mesoporous silica nanoparticles.
Wang S; Liu F; Li XL
Chem Commun (Camb); 2017 Aug; 53(62):8755-8758. PubMed ID: 28726871
[TBL] [Abstract][Full Text] [Related]
20. Hybrid Mesoporous Silica-Based Drug Carrier Nanostructures with Improved Degradability by Hydroxyapatite.
Hao X; Hu X; Zhang C; Chen S; Li Z; Yang X; Liu H; Jia G; Liu D; Ge K; Liang XJ; Zhang J
ACS Nano; 2015 Oct; 9(10):9614-25. PubMed ID: 26316321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
